Systematic review with meta-analysis: The prevalence of bile acid malabsorption in the irritable bowel syndrome with diarrhoea

Alimentary Pharmacology and Therapeutics

Volumn 42, Issue 1, 2015, Pages 3-11

  Slattery, S A ^a   Niaz, O ^b   Aziz, Q ^a   Ford, A C ^c,d   Farmer, A D ^a,e  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b BLACKPOOL VICTORIA HOSPITAL   (United Kingdom)

^c ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^d UNIVERSITY OF LEEDS   (United Kingdom)

^e UNIVERSITY HOSPITALS OF NORTH MIDLANDS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

23 SELENO 25 HOMOTAUROCHOLIC ACID; TAUROCHOLIC ACID; UNCLASSIFIED DRUG; BILE ACID;

BILE ACID MALABSORPTION; CLINICAL PRACTICE; DIAGNOSTIC ACCURACY; DIARRHEA; HUMAN; MALABSORPTION; META ANALYSIS; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; QUALITY CONTROL; RETROSPECTIVE STUDY; REVIEW; SOCIOECONOMICS; SYSTEMATIC REVIEW; ADULT; IRRITABLE BOWEL SYNDROME; MALABSORPTION SYNDROMES; METABOLISM; PATHOPHYSIOLOGY;

ADULT; BILE ACIDS AND SALTS; DIARRHEA; HUMANS; IRRITABLE BOWEL SYNDROME; MALABSORPTION SYNDROMES; PREVALENCE;

EID: 84930479434     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13227     Document Type: Review

References (46)

1. Drossman DA,. Rome III: The Functional Gastrointestinal Disorders. 3rd ed. McLean, VA: Degnon Associates, 2006.
2. Lovell RM, Ford AC,. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gas-troenterol Hepatol 2012; 10: 712-21. e4.
3. Canavan C, West J, Card T,. Review article: the economic impact of the irritable bowel syndrome. Aliment Pharmacol Ther 2014; 40: 1023-34.
4. Chang L, Lembo A, Sultan S,. American gastroenterological association institute technical review on the pharmacological management of irritable bowel syndrome. Gastroenterology 2014; 147: 1149-72. e2.
5. Corsetti M, Van Oudenhove L, Tack J,. The quest for biomarkers in IBS-where should it lead us? Neurogastroenterol Motil 2014; 26: 1669-76.
6. Canavan C, West J, Card T,. The epidemiology of irritable bowel syndrome. Clin Epidemiol 2014; 6: 71-80.
7. Ohman L, Tornblom H, Simren M,. Crosstalk at the mucosal border: importance of the gut microenvironment in IBS. Nat Rev Gastroenterol Hepatol 2015; 12: 36-49.
8. Neal KR, Barker L, Spiller RC,. Prognosis in post-infective irritable bowel syndrome: a six year follow up study. Gut 2002; 51: 410-3.
9. Ghoshal UC, Ranjan P,. Post-infectious irritable bowel syndrome: the past, the present and the future. J Gastroenterol Hepatol 2011; 26 (Suppl. 3): 94-101.
10. Wedlake L, A'Hern R, Russell D, Thomas K, Walters JR, Andreyev HJ,. Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2009; 30: 707-17.
11. Peters AM, Walters JR,. Recycling rate of bile acids in the enterohepatic recirculation as a major determinant of whole body 75SeHCAT retention. Eur J Nucl Med Mol Imaging 2013; 40: 1618-21.
12. Roberts MS, Magnusson BM, Burczynski FJ, Weiss M,. Enterohepatic circulation: physiological, pharmacokinetic and clinical implications. Clin Pharmacokinet 2002; 41: 751-90.
13. Camilleri M,. Advances in understanding of bile acid diarrhea. Expert Rev Gastroenterol Hepatol 2014; 8: 49-61.
14. Vijayvargiya P, Camilleri M, Shin A, Saenger A,. Methods for diagnosis of bile acid malabsorption in clinical practice. Clin Gastroenterol Hepatol 2013; 11: 1232-9.
15. Williams AJ, Merrick MV, Eastwood MA,. Idiopathic bile acid malabsorption-a review of clinical presentation, diagnosis, and response to treatment. Gut 1991; 32: 1004-6.
16. Ford AC,. Applicability of the reported prevalence of bile salt malabsorption in irritable bowel. Aliment Pharmacol Ther 2010; 31: 161-2; author reply 162-4.
17. Liberati A, Altman DG, Tetzlaff J, et al,. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009; 339: b2700.
18. Whiting PF, Rutjes AW, Westwood ME, et al,. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011; 155: 529-36.
19. DerSimonian R, Laird N,. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88.
20. Borenstein M,. Introduction to Meta-analysis. Oxford: Wiley, 2009.
21. Gracie DJ, Kane JS, Mumtaz S, Scarsbrook AF, Chowdhury FU, Ford AC,. Prevalence of, and predictors of, bile acid malabsorption in outpatients with chronic diarrhea. Neurogastroenterol Motil 2012; 24: 983-e538.
22. Dhaliwal A, Chambers S, Nwokolo C, et al,. Bile acid diarrhoea. Gut 2013; 62 (Suppl. 1): A122.
23. Smith MJ, Cherian P, Raju GS, Dawson BF, Mahon S, Bardhan KD,. Bile acid malabsorption in persistent diarrhoea. J R Coll Physicians Lond 2000; 34: 448-51.
24. Kurien M, Evans KE, Leeds JS, Hopper AD, Harris A, Sanders DS,. Bile acid malabsorption: an under-investigated differential diagnosis in patients presenting with diarrhea predominant irritable bowel syndrome type symptoms. Scand J Gastroenterol 2011; 46: 818-22.
25. Bajor A, Tornblom H, Rudling M, Ung KA, Simren M,. Increased colonic bile acid exposure: a relevant factor for symptoms and treatment in IBS. Gut 2015; 64: 84-92.
26. Aziz I, Mumtaz S, Boholah H, Chowdhury FU, Sanders DS, Ford AC,. High Prevalence of Idiopathic Bile Acid Diarrhea Among Patients With Diarrhea-predominant Irritable Bowel Syndrome Based on Rome III Criteria. Clin Gastroenterol Hepatol 2015; pii: S1542-3565(15)00249-9. doi: 10.1016/j.cgh.2015.03.002. [Epub ahead of print].
27. Spiller RC,. Irritable bowel syndrome. Br Med Bull 2004; 72: 15-29.
28. Key statistics for local authorities in England and Wales.
29. Halder SL, Locke GR 3rd, Schleck CD, Zinsmeister AR, Melton LJ 3rd, Talley NJ,. Natural history of functional gastrointestinal disorders: a 12-year longitudinal population-based study. Gastroenterology 2007; 133: 799-807.
30. Townsend N, Wickramasinghe K, Bhatnagar P, et al,. Coronary Heart Disease Statistics 2012 Edition. London: British Heart Foundation, 2012.
31. Barkun AN, Love J, Gould M, Pluta H, Steinhart H,. Bile acid malabsorption in chronic diarrhea: pathophysiology and treatment. Can J Gastroenterol 2013; 27: 653-9.
32. Wilcox C, Turner J, Green J,. Systematic review: the management of chronic diarrhoea due to bile acid malabsorption. Aliment Pharmacol Ther 2014; 39: 923-39.
33. Beigel F, Teich N, Howaldt S, et al,. Colesevelam for the treatment of bile acid malabsorption-associated diarrhea in patients with Crohn's disease: a randomized, double-blind, placebo-controlled study. J Crohns Colitis 2014; 8: 1471-9.
34. Ford AC, Bercik P, Morgan DG, Bolino C, Pintos-Sanchez MI, Moayyedi P,. Validation of the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care. Gastroenterology 2013; 145: 1262-70. e1
35. Dang J, Ardila-Hani A, Amichai MM, Chua K, Pimentel M,. Systematic review of diagnostic criteria for IBS demonstrates poor validity and utilization of Rome III. Neurogastroenterol Motil 2012; 24: 853-e397.
36. Sanders DS, Carter MJ, Hurlstone DP, et al,. Association of adult coeliac disease with irritable bowel syndrome: a case-control study in patients fulfilling ROME II criteria referred to secondary care. Lancet 2001; 358: 1504-8.
37. Halpin SJ, Ford AC,. Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2012; 107: 1474-82.
38. Ford AC, Spiegel BM, Talley NJ, Moayyedi P,. Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2009; 7: 1279-86.
39. National institute of health and care excellence. Irritable Bowel Syndrome in Adults. London: National Institute for Health and Care Excellence, 2008.
40. Hungin AP, Molloy-Bland M, Claes R, et al,. Systematic review: the perceptions, diagnosis and management of irritable bowel syndrome in primary care-a Rome Foundation working team report. Aliment Pharmacol Ther 2014; 40: 1133-45.
41. Camilleri M, Shin A, Busciglio I, et al,. Validating biomarkers of treatable mechanisms in irritable bowel syndrome. Neurogastroenterol Motil 2014; 26: 1677-85.
42. Pattni S, Walters JR,. Recent advances in the understanding of bile acid malabsorption. Br Med Bull 2009; 92: 79-93.
43. Aziz I, Kurien M, Sanders DS, Ford AC,. Screening for bile acid diarrhoea in suspected irritable bowel syndrome. Gut 2015; 64: 851.
44. Excellence National Institute of Health and Clinical Excellence. Diagnostics Consultation Document: SeHCAT (tauroselcholic [75selenium] acid) for the Investigation of Diarrhoea Due to Bile Acid Malabsorption. London: National Institute of Health and Care Excellence, 2012.
45. Vanner SJ, Depew WT, Paterson WG, et al,. Predictive value of the Rome criteria for diagnosing the irritable bowel syndrome. Am J Gastroenterol 1999; 94: 2912-7.
46. Riemsma R, Al M, Corro Ramos I, et al,. SeHCAT [tauroselcholic (selenium-75) acid] for the investigation of bile acid malabsorption and measurement of bile acid pool loss: a systematic review and cost-effectiveness analysis. Health Technol Assess 2013; 17: 1-236.